Covidien target raised to $55 from $49 at Lazard Capital
Lazard Capital has increased conviction in Covidien shares following the company's Q4 results and presentation at the firm's conference. Lazard Capital keeps a Buy rating on the stock and raised its target price to $55. :theflyonthewall.com
News For COV From The Last 14 Days
Check below for free stories on COV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
